Bora Completes Acquisition of US Sterile Fill/Finish Facility From Emergent
Bora Pharmaceuticals Co., Ltd. recently announced it has completed the acquisition from Emergent BioSolutions of its sterile manufacturing facility in Baltimore-Camden, MD. The facility adds drug product fill/finish to Bora’s extensive biologics drug substance capabilities.
The newly acquired 87,000-sq-ft facility provides drug product manufacturing services for sterile injectables and offers clinical and commercial non-viral aseptic fill/finish services of vials and pre-filled syringes on four fill lines, lyophilization, formulation development, and support services.
“Following on the heels of our recent acquisition of Upsher-Smith Laboratories, the Camden facility extends our presence in North America, expands our offering for our biologics customers, and advances us further in our goal to become a full service global CDMO,” said Bobby Sheng, Chairman and CEO of Bora Group. “We look forward to further enhancing the capabilities at the site and welcoming the hugely talented team in Camden to our global family.”
Bora completed the acquisition of Upsher-Smith Laboratories, the Minnesota-based generics manufacturer and marketer, in April 2024, adding oral dose capabilities at two facilities in Plymouth and Maple Grove, Minnesota. The Company’s extensive global CDMO network now includes ten high quality manufacturing facilities serving customers across dose forms and delivery technologies.
Gibson, Dunn & Crutcher LLP served as legal counsel to Bora in the acquisition.
Founded in 2007, Bora Pharmaceutical Co., Ltd. is the largest pharmaceutical manufacturer in Taiwan with well-connected global distribution to supply more than 100 countries around the world. Bora is dedicated to becoming a global leader in pharmaceutical manufacturing by offering its clients the best quality, efficiency, and reliability. For more information, visit www.bora-corp.com.
Total Page Views: 545
